Key levels and trade conditions
Delayed quotes · Technical conditionsShowing the near-term range, based on the latest 5 completed sessions and updated after each close.
Above the breakout line; await close and volume confirmation
Signals require closing-price and volume confirmation; review the company research below before acting.
When does defense take priority?
Close beyond this level with session volume ≥ 1.5× the previous 20 completed sessions’ average.
Confirmed close below $96.19 → consider reducing
When to consider adding?
Close beyond this level with session volume ≥ 1.5× the previous 20 completed sessions’ average.
Confirmed close above $109.83 → consider a staged addition
01Newstock overall assessment
The conclusion first, followed by the evidence that matters most.
Watch — await combined confirmation. An entry assessment has not yet been established.
02What happened recently
Company events, industry developments and market conditions — facts separated from possible explanations.
US 10Y yield 5.13%2026-11-13T16:39:54.000Z
VIX 20.222026-11-13T16:39:46.000Z
Dollar index 103.362026-11-13T16:44:56.000Z
Market and sector reference
CLX +1.57% · SPY -0.94% · Peer average +1.69% (CL, EL, GIS, HSY, KDP, KHC)
2026-11-13T16:55:33.000Z · Yahoo · Aligned-session reference, not a causal attribution.
Related news and impact paths
Recent news related to this stock
6 direct · 0 2nd-order · 0 thematicRanked by model assessment and recency. Labels use the original model impact, not expected returns. Impact percentages are model estimates, not observed price changes, probabilities or guaranteed returns.
- #1Impact6.5%AdverseDirectClorox Now Expects Earnings Near the Low End of Its Forecast as Costs Rise. Should Dividend Investors Be Worried?10d ago
Management guiding earnings toward the low end signals that input, logistics or promotional costs are pressuring a 45%+ gross margin base, and investors will reassess the sustainability of Clorox’s dividend profile.
Also named: PG · KMB · KO · PEP
On a $7.1B revenue base with near-flat growth, macro headwinds first show up as weaker pricing pass-through and volume pressure, making it hard to expand a 45.2% gross margin.
Also named: PROCTER & GAMBLE · CHURCH & DWIGHT · IP · PKG · WRK · KMB
The company directly flagged inflation and margin pressure, indicating pricing and cost pass-through are still not fully offsetting input-cost inflation.
Also named: PG · KMB · COST · IP · PKG · GPK
A firmer full-year margin or cash-flow outlook could help narrow Clorox’s valuation discount.
Also named: PG · CL · KMB · KO · PEP · GIS
The company directly reported a Q1 beat on revenue and earnings, with cost savings supporting margin repair and likely lifting full-year EPS expectations.
Also named: PG · KMB · CL · CHD
The company is directly reporting earnings and guidance; if EPS, gross margin, and full-year outlook modestly exceed a fairly dispersed consensus, that should lift earnings expectations, though upside should be capped because some margin recovery was already anticipated.
Also named: CHURCH & DWIGHT · PROCTER & GAMBLE · RECKITT BENCKISER · KMB · PG · GIS
03Is the company worth considering?
Business quality, financials, valuation and analyst disagreements.
🏛️ Company factsSEC filings + FINRA official data
Annual revenue $7.1B · latest quarter up 33.3% YoY · reported FY net income of $810M · short-sale volume share below its recent available-day average.
FY revenue
$7.1B
2025-06
Latest Q YoY
+33.3%
Gross margin
45.2%
FY net income
$810M
Diluted EPS
$6.56
Short-sale volume share
47.2%
2026-11-05 · Recent available-day avg 60% · below recent average
Short-sale volume as a share of trades covered by the FINRA file, not all market trading or outstanding short positions. Changes do not establish that short sellers are adding or covering positions.
🐋 Ownership filings (last 180 days)
Recent 13D/13G beneficial ownership filings, which may include amendments. A filing does not establish a recent purchase or a current holding, and its form type alone does not establish investment intent. Read the original filing for details.
- 2026-11-10SCHEDULE 13GInvesco Ltd.
- 2026-10-27SCHEDULE 13G/ABlackRock, Inc.
Historical results versus analyst expectations
🎯 Market expectations
Estimate context score Low · 34/100Nasdaq analyst consensus · currently available data
This data has a low context score. Analyst coverage, disagreement, or revisions may limit its usefulness. Review the estimate range and underlying data.
- Sep 2026$1.55 vs $0.97+59.79%
- Jun 2026$1.66 vs $1.64+1.22%
- Mar 2026$1.64 vs $1.48+10.81%
- Dec 2025$1.39 vs $1.43-2.8%
Analyst estimates, not our forecast · not investment advice
Analyst consensus and disagreement
Target-price summary $74.00–$105.00 · Consensus $90.42
Buy / hold / sell 0 / 10 / 3
Nasdaq · Retrieved 2026-11-13T16:57:23.871Z · The aggregate does not provide individual report dates or original theses. It does not establish undervaluation; no analyst rationale is inferred. Targets are not guaranteed outcomes.
Next-quarter EPS estimate (Dec 2026) $1.12 · $0.90–$1.57 · 7 analysts
Four-week estimate revisions: up / down 0 / 5
Estimate dispersion 59.8%
Nasdaq EPS forecasts · retrieved 2026-11-13T16:57:23.724Z04Is now a good time?
Trend, moving averages, volume and key price levels — not the decline alone.
Technical structure · Uptrend structure
MA5 $105.43
MA10 $99.77
MA20 $93.36
MA60 $90.76
Last completed-session close $108.20 (+1.25%) · Volume / prior 20-session average 1.23×
Prior 20-session range $84.43–$109.83 · MA20 change over five sessions +5.86% · CMF20 0.24
Confirmation to watch: a close above $109.83 with volume at least 1.5× the prior 20-session average. A heavy-volume break below $84.43 weakens the setup.
Completed daily candles only. Daily OHLCV cannot establish accumulation, shakeout or manipulation intent; CMF is a price/volume proxy, not actual fund flows. Thresholds are research rules, not validated success probabilities. Yahoo · 2026-11-12
Price and news
Historical prices and volume. Drag to pan; scroll to zoom.
Related news
05What would change our assessment?
Conditions for reconsidering entry and developments that invalidate the thesis.
Complete the company and technical cross-check before defining entry and invalidation conditions.
Additional risk evidence and model detail
Market View
Crowding
Risk temperature
Tail risk
Triggers
Price and volume
Insider signals
See every affected stock, second-order impact and risk factor. Try Pro free for 7 days — no credit card required.
Start my free trial